BioMarin Pharmaceutical Inc.

BioMarin stock jumped about 5% on news of a global settlement with Ascendis Pharma over the Yuviwel patent dispute. Ascendis will pay BioMarin 20% of U.S. Yuviwel sales and 18% of EU, Brazil, South Ko